MAHA Reforms and FDA Policy Shifts: What In-House Teams Must Review in Food, Drug and Supplement Contracts

What the MAHA Reform Agenda Actually Changes in Regulatory Terms

The Department of Health and Human Services has published an eighteen-month retrospective crediting Secretary Robert F. Kennedy Jr. with a wave of reforms under the Make America Healthy Again banner. The headline actions include a review of Generally Recognised as Safe (GRAS) determinations for food additives, tightened scrutiny of synthetic dyes, accelerated enforcement against certain ultra-processed ingredient categories, and a stated intent to modernise dietary supplement oversight. For lawyers and procurement teams, the relevant question is not whether these reforms are good politics. The relevant question is which contractual obligations, representations and warranties they disturb.

The short answer is: quite a few.

GRAS Review and the Contractual Representation Problem

The GRAS self-affirmation process has long allowed food manufacturers to introduce ingredients without formal FDA pre-approval. The MAHA agenda specifically targets this pathway, signalling that previously settled ingredient approvals may be reopened. Several synthetic dyes, including Red 3, have already faced accelerated withdrawal timelines.

The contractual problem emerges immediately in two places. First, supplier agreements in the food and beverage sector commonly contain representations that ingredients comply with all applicable laws and hold all necessary regulatory clearances. If a GRAS determination is rescinded or formally questioned, that representation becomes potentially inaccurate mid-contract. Second, product formulation agreements and co-manufacturing contracts often specify ingredients by name or by approved-additive lists. A forced reformulation triggered by regulatory action can constitute a material change, activating renegotiation rights or, in some drafting, a force majeure or change-in-law clause.

In-house teams should audit every supplier contract to confirm whether a change-in-law provision covers regulatory guidance changes and not only enacted statutes. Guidance-driven enforcement, which is the primary tool HHS is currently deploying, often falls into a grey zone that poorly drafted clauses do not address.

Dietary Supplement Oversight and Distribution Agreement Risk

The MAHA programme explicitly targets the supplement sector, promising enhanced post-market surveillance and potential pre-market notification requirements. The current framework under the Dietary Supplement Health and Education Act of 1994 imposes relatively light obligations. Any move toward mandatory pre-market review, even if implemented through guidance rather than legislation, changes the risk profile of distribution and retail supply agreements fundamentally.

Distributors and retailers typically require suppliers to warrant that products are lawfully marketed and that all required notifications have been filed. If HHS introduces new notification requirements by guidance or enforcement policy, a supplement company that has not complied could inadvertently be in breach of multiple downstream contracts simultaneously. Indemnification clauses in distribution agreements become the critical line of defence. Many were drafted when the regulatory baseline was stable. They need reviewing now.

Supply Chain Terms and the Ultra-Processed Food Classification

One of the more commercially disruptive aspects of the MAHA agenda is its targeting of ultra-processed foods. Although no single statutory definition of ultra-processed has yet been enacted, HHS and the FDA have signalled purchasing and procurement guidance, particularly in relation to federal nutrition programmes such as school meals and SNAP-linked retail standards.

Contracts with institutional buyers, including government-adjacent purchasers such as hospital networks, school boards and military contractors, frequently incorporate by reference applicable federal nutritional standards. A policy shift in those standards, even one implemented through programme guidance rather than binding regulation, can trigger compliance obligations embedded in those supply contracts without any fresh negotiation occurring. Procurement teams at food manufacturers should map every contract that incorporates federal nutrition programme terms by reference and assess the exposure.

What In-House Teams Should Renegotiate or Watch Right Now

Four categories of action are worth prioritising. First, revisit ingredient representation and warranty clauses in all supplier and co-manufacturer agreements, specifically to address the possibility of mid-term GRAS withdrawal or additive delisting. Carve-outs for regulatory-driven reformulation, with agreed timelines and cost-allocation mechanisms, are worth negotiating proactively rather than under pressure.

Second, review indemnification structures in supplement distribution agreements to ensure that the party best placed to monitor regulatory change, typically the manufacturer, bears the primary compliance risk and the cost of any resulting breach.

Third, check every contract that incorporates federal nutrition or food safety standards by reference. Understand precisely which version of those standards is incorporated: a static reference to standards as of the contract date, or a rolling reference to standards as amended. The latter creates automatic compliance obligations whenever HHS updates its guidance.

Fourth, consider whether material adverse change clauses in M&A or financing agreements touching the food, supplement or ingredients sectors adequately capture the risk of accelerated regulatory change. Buyers and lenders active in these spaces should be asking sellers and borrowers for detailed regulatory risk disclosures as part of due diligence.

The Broader Pattern: Policy-Driven Contractual Disruption

The MAHA reforms illustrate a pattern that has become a consistent feature of the current US administration's approach: using agency guidance, enforcement prioritisation and programme conditions rather than legislation to shift regulatory baselines quickly. As one HHS document notes, the ambition is to deliver "historic reforms" within a single term. The speed itself is the compliance challenge.

Contracts are written for a regulatory environment that existed at signing. When that environment shifts faster than contract cycles, the parties that suffer most are those whose agreements assumed stability. Sophisticated in-house teams are already treating regulatory velocity as a contract drafting variable rather than a background assumption. The MAHA agenda is a clear prompt to do the same in every sector it touches.